Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation

Bone Marrow Transplantation
M PodestàA Bacigalupo

Abstract

Allogeneic bone marrow transplant recipients maintain normal peripheral blood counts long term, suggesting durable support from engrafted stem cells. In order to investigate late hemopoietic reconstitution at the level of committed and early progenitors (LTC-IC), we studied 64 long-term survivors at a median interval of 6 years (range: 2-20) after allogeneic bone marrow transplant. CFU-GM and BFU-E numbers did not differ from normal controls; CFU-GEMM were found to be significantly decreased (1.2 +/- 0.2/10(5) vs 3.1 +/- 0.4, P = 0.001). The most remarkable defect was however, the low frequency of LTC-IC (3.2 +/- 0.6/10(6) vs 54.2 +/- 9.3, P = 0.0001) that did not improve with time and did not correlate with phase of the disease, conditioning regimen, CMV infections or GVHD. Number of infused cells and CFU-GM content of marrow grafts did not seem to influence the number of LTC-IC. This study documents a significantly reduced number of early progenitors in BMT patients despite normal numbers of committed progenitors and normal peripheral blood counts. This finding may suggest a permanent reduction of the stem cell reservoir after allogeneic bone marrow transplantation.

Citations

Mar 29, 2001·Experimental Hematology·M PodestàA Bacigalupo
Nov 13, 2008·Cytotechnology·Andrew D ClarkTessa L Holyoake
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Guillaume CartronJorge Domenech
Oct 31, 2000·Current Opinion in Hematology·M SadelainI Rivière
Oct 18, 2001·Current Opinion in Hematology·M Podestà
Jul 19, 2011·Blood Reviews·Shahinaz M Gadalla, Sharon A Savage
Aug 12, 2008·The Lancet Oncology·Francesco FrassoniAndrea Bacigalupo
Aug 4, 2004·Leukemia Research·Monika EngelhardtYalin Guo
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ravi BhatiaSmita Bhatia
Jul 27, 2001·Blood·M Engelhardt, J Finke
Dec 12, 2001·British Journal of Haematology·J ScopesF M Gibson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.